| « ADVR Message list | Reply to msg. | Post new msg. | « Older | Newer » |
| LETTER
FROM THE CEO April 2004 To our Valued Shareholders: As the new CEO of Advanced Viral Research Corp., I am delighted to be on board and am excited about the future. Although we have recently filed our 10K with the SEC, I wanted to reach out to you - our shareholders - in a more personal way. Our shareholders are the backbone of our Company and we thank you for your support. As part of a new, open communications plan, I wanted to share some of our future plans and upcoming events with you. STRATEGY Since starting in mid-February, I have been focused on major business initiatives and strategic direction. We remain dedicated to our mission of introducing AVR118 to patients and are taking all of the necessary steps to make this possible. It is my experience that a solid strategic direction is critical to the success of any company. To this end, I am developing a cogent and focused strategy with very clear objectives. It is my personal commitment, as well as that of the Company, to deliver on those objectives in a timely fashion. As you know, drug development is a long and costly endeavor that is done under the auspices of the Food and Drug Administration (FDA) in the United States. I have spent the last two decades in drug development and know first-hand what it takes to get a product approved by the FDA for marketing. The only way forward for Advanced Viral is to remain focused on conducting high-quality clinical trials on AVR118 in the United States in accordance with FDA regulations. It is paramount that we lay a solid foundation in working with the FDA and conduct clinical trials in accordance with Good Clinical Practices. We will also be paying a great deal of attention to other, relevant operations which are equally important in drug development such as quality control, quality assurance, and manufacturing. It is our hope that the clinical trials in Israel will help facilitate the trials in the United States; however, it is important to point out that any clinical trial is unpredictable and there can be no assurances as to start date, enrollment rate and completion date. While data cannot be disclosed on an ongoing basis due to the need for data verification and database validation, we are encouraged by the early findings in our Israeli trials and anticipate completion by the end of the second quarter this year. COMMUNICATION We recognize that regular, clear and accurate communication is essential. We have some exciting upcoming events, which include: Presentation at ASCO: We will be presenting a poster at The American Society of Clinical Oncology's (ASCO) 40th Annual Meeting in June of this year. ASCO is the world's leading professional organization representing physicians who treat people with cancer and we are thrilled to be invited to such a prestigious conference. As you probably are aware, any information regarding the presentation is under embargo by ASCO until the day of the presentation. Presentation at an Equities Conference: We will be presenting at the Symposium's Small Cap Equities Conference on June 2nd at the Roosevelt Hotel in New York City. «Meet the CEO» Sessions: I anticipate setting up a road show to meet with investors personally in May in Boston, New York and Florida should there be sufficient interest from our shareholders. Please e-mail Veronica Welch at ronnie@cwrpartners.com if you are interested in attending. I look forward to meeting with as many investors as possible. Open-house: We will host an open-house event at our corporate headquarters in Yonkers, NY in July. Please contact Maria Marino at mariag@adviral.com for a reservation. Quarterly updates: We will be giving quarterly updates either by conference call or by letters such as this one. E-Communication: We are revamping our web site to make it more user-friendly and informative. We will also introduce an e-mail system whereby investors can automatically receive press releases and updates via e-mail. An overhaul will also be done for our investor relations and media kits. Media: We continue to speak with the national media on a daily basis regarding the benefits of AVR118. This campaign will be stepped up during the second half of the year. On a final note, the values with which I will drive the Company are integrity and honesty. I appreciate your continued support of our company and, most of all, thank the employees for their dedication and tenacity. You can rest assured that we are working aggressively to meet all of our strategic objectives. Please continue to refer to our web site for investor updates and press releases. Sincerely, Elma S. Hawkins, PhD, MBA President and Chief Executive Officer Note: The information contained herein contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to complete the clinical trials of AVR118. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. ******************************************************** IAG.....-kevtod |
| I
like that she is "delighted & excited"...... I am wondering if she has any intention to share this plan publicly with the shareholders..... "It is my experience that a solid strategic direction is critical to the success of any company. To this end, I am developing a cogent and focused strategy with very clear objectives. It is my personal commitment, as well as that of the Company, to deliver on those objectives in a timely fashion."..... .....So that we can judge the timeliness of her commitments, or if we will still be required to just believe that there is such a plan in place ??? I also want her to stop uising the word "hope"....As in "It is our hope that the clinical trials in Israel will help facilitate the trials in the United States;" Good Stuff~.....-kev |
another view edited for the laymen that do not believe in the company management
| To
our Valued Shareholders: Hmmmmmmmmmmm!!!!!!!!!! As the new CEO of Advanced Viral Research Corp., I am delighted and tickeled pink to be on board and I am really excited about the big salary and options on new tires. Although we have recently filed our 10K with the SEC, I wanted to reach out to you - our gullable shareholders - in a more personal way so that I can justify the warrants that will be coming my way soon. Our shareholders are the limp backbone of our Company and we thank you for your jello-like support. As part of a new, second generation open communications plan, I wanted to share some of our future schemes and plans and upcoming pony shows with you. STRATEGY Since starting in mid-February, I have been focused on major business initiatives, strategic direction, and this hunk they call Eli. We (he and I)remain dedicated to our mission of introducing AVR118 to patients eventually and WE are taking all of the necessary steps to make this possible sometime in the next decade or two. It is my experience that a solid strategic direction is critical to juicing a company for all you can get. To this end, I am developing a cogent and focused strategy with very clear persoanl objectives. It is my personal commitment to me, as well as that of the Company to keep a nostril just above the water, and to deliver on those objectives in a timely fashion just like we promised 18 years ago. As you damn well know, drug development is a long and costly endeavor that is done under the auspices of the Food and Drug Administration (FDA) in the United States and not in Israel. I have spent the last two decades in drug development and know first-hand what it takes to get a product approved by the FDA for marketing- lots of f-ing money for one thing. The only way forward for Advanced Viral is to remain focused on conducting high-quality clinical trials on AVR118 in the United States in accordance with FDA regulations which will require a hell of a lot more dilution and greedy idiots like you folks to suck it up. It is of paramount importance that we use correct English, proofread our web page and lay a solid foundation in working with the FDA while conducting clinical trials in accordance with Good Clinical Practices and all that. We will also be paying lots of good old boy consultants a bunch of money and we will put a great deal of attention to other, relevant operations which are equally important in drug development such as quality control, quality assurance, and manufacturing and chit like that. It is our hope that the clinical trials in Israel will help convince more idiots to buy our stock and maybe facilitate the trials in the United States; however, it is important to point out that any clinical trial is unpredictable and there can be no assurances as to start date, enrollment rate and completion date and when it comes to ADVR, no assurance that we will even finish the trial. While data cannot be disclosed on an ongoing basis due to the need for data verification and database validation, we are encouraged by the early findings in our Israeli trials and anticipate completion by the end of the second quarter this year or sometime there after. COMMUNICATION We recognize that regular, clear and accurate communication is essential to fooling the puplic. So we cooked up some exciting upcoming events, which include: Presentation at ASCO: We will be presenting a poster at The American Society of Clinical Oncology's (ASCO) 40th Annual Meeting in June of this year. ASCO is the world's leading professional organization representing physicians who treat people with cancer and we are thrilled to be invited to such a prestigious conference- ha ha. As you probably are aware, any information regarding the presentation is under embargo by ASCO until the day of the presentation- top secret stuff- read between the lines. Presentation at an Equities Conference: We will be presenting at the Symposium's Small Cap Equities Conference on June 2nd at the Roosevelt Hotel in New York City where we will grovvel for money again. «Meet the CEO» Sessions: I anticipate setting up a road show to meet with investors personally in May in rarBoston, enoughalreadyNewYork and anywhere in Florida except Sarasota should there be sufficient interest from our shareholders. Please e-mail Veronica Welch at ronnie@cwrpartners.com if you are interested in attending unless you are a basher. I look forward to meeting with as many investors as possible as long as you are from New Jersey. Open-house: We will host an open-house event at our corporate headquarters in Yonkers, NY in July. Please contact Maria Marino at mariag@adviral.com for a reservation. We promise better cookies and Ed will have a seat on the podium. Quarterly updates: We will be giving quarterly updates either by conference call or by letters such as this one- sure. E-Communication: We are revamping our web site to make it more user-friendly and informative. We will also introduce an e-mail system whereby investors can automatically receive press releases and updates via e-mail. An overhaul will also be done for our investor relations and media kits. Anyone getting a response from an actual human being will get extra cookies at their Yonkers tour. Media: We continue to speak with and try to con the national media on a daily basis regarding the benefits of AVR118. This campaign will be stepped up during the second half of the year because we anticipate some real problems then. On a final note, the values with which I will drive the Company are integrity, honesty and sincerity- if you can fake all that, you've got it made. I appreciate your continued dubious support of our company and, most of all, thank the pitifully few employees for their dedication, tenacity and desparation. You can rest assured that we are working aggressively to meet all of our strategic and personal objectives. Please continue to refer to our web site for investor updates, press releases and other crapola that we may publish there. |
| The
management has iterated, re-iterated and now re-re-iterated they expect Israeli Trial results in Q2 of 2004. Hard to believe they can be so stupid as to continue to tell investors the Trial will be complete THIS quarter and then miss. I assume they will complete the Trial this quarter. B..ahhh..utttt!!!! They have the announcement OUT. What did the say it would cost to review the data? Over $100,00.00? So the question is, when will they announce the results of the Trial? I would like to see The Boss address that in her next communique. Is this a new and improved version of ADVR or just a limp change of management? I hope for, oh heck, I expect the best. (Voluntary Disclosure: Position- Long) |